文献速递甲状腺疾病

甲状腺乳头状癌患者治疗过程中生活质量效应的测量与评估变异

Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2016-12-15

本研究对117例甲状腺乳头状癌患者在治疗第一年三个围手术期时间点使用四种效用量表(SF6D、EQ5D、HUI2、HUI3)评估健康相关生活质量,比较天花板效应、组内相关系数、效应量和质量调整生命年。结果显示所有量表评分在术后两周下降、六个月恢复至治疗前水平,SF6D是唯一在所有三个时间点间均超过常规最小重要差异的量表,作者认为SF6D对治疗效应最敏感。

要点

  • 117例甲状腺乳头状癌患者中27%术前有焦虑或抑郁诊断,41%有区域淋巴结转移,49%接受辅助放射性碘治疗。
  • 四种量表指数评分范围为0.77(SF6D)至0.90(EQ5D),所有评分术后两周下降、六个月恢复至治疗前水平。
  • SF6D是唯一在所有三个时间点间均超过常规最小重要差异的量表,作者认为其对该人群治疗效应最敏感。

核心结论

  • 研究结果反映甲状腺乳头状癌患者总体健康状况良好,生活质量影响主要与治疗的情感和社交影响相关。
  • 四种量表测量相似的潜在构念,但在检测健康变化方面存在变异。
  • 在评估的量表中,SF6D对治疗效应最敏感,作者建议在该患者群体未来的经济学分析中使用SF6D。

研究设计与样本

  • 对117例诊断为甲状腺乳头状癌的患者,在治疗第一年三个围手术期时间点施测四种常用健康相关生活质量问卷(SF6D、EQ5D、HUI2、HUI3)。
  • 评估临床病理与治疗过程数据对健康相关生活质量的影响,包括手术并发症、因持续/早期复发再手术和辅助放射性碘治疗。
  • 比较四种量表的标准指标,包括天花板效应、组内相关系数、效应量和质量调整生命年。

主要发现

  • 117例患者中27%术前有焦虑或抑郁诊断,41%有区域淋巴结转移,3例有远处转移,49%接受辅助放射性碘治疗。
  • 天花板效应(即获得满分者比例)以EQ5D最大、SF6D最小。
  • 指数评分范围为0.77(SF6D)至0.90(EQ5D)。
  • 所有评分在术后两周下降,六个月恢复至治疗前水平。
  • SF6D是唯一在所有三个时间点间均超过常规最小重要差异的量表。

临床怎么用

  • 作者认为,在评估的量表中SF6D对治疗效应最敏感,应在此类患者群体未来的经济学分析中使用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid cancer incidence is increasing. The effect of diagnosis and treatment on health-related quality of life (HRQoL) is an essential variable in the absence of a change in life span for the majority of patients. HRQoL instruments, with data useful for between-disease comparisons, are being increasingly used for health policy and outcomes evaluation. Variation exits among the instruments based on the impact of a specific disease. We assessed which of four well-validated, preference-based surveys detect changes in health and clinical intervention in patients diagnosed with papillary thyroid cancer (PTC). METHODS: Four commonly used HRQoL questionnaires (Short Form-12v2® [SF6D], EuroQol-5D [EQ5D], and Health Utilities Index Mark 2 and 3 [HUI2, HUI3]) were administered to patients with the diagnosis of PTC at three perioperative time points during the first year of treatment. Clinicopathological and treatment course data were assessed for HRQoL impact including complications from surgery, re-operation for persistence/early recurrence, and adjuvant radioactive iodine treatment. We compared standard metrics, including ceiling effect, intraclass correlation coefficient, effect sizes, and quality-adjusted life-years between the four instruments. RESULTS: Of 117 patients, 27% had a preoperative diagnosis of anxiety or depression, 41% had regional lymph node metastases, three had distant metastases and 49% underwent adjuvant radioactive iodine treatment. The ceiling effect (i.e., proportion with a perfect score) was greatest with EQ5D and least with SF6D. Index scores ranged from 0.77 (SF6D) to 0.90 (EQ5D). All scores declined at two weeks postoperatively and returned to pretreatment levels at six months. The SF6D was the only instrument to exceed the conventional minimally important difference between all three time points. Quality-adjusted life-years were as follows: SF6D, 0.79; EQ5D, 0.90; HUI2, 0.88; and HUI3, 0.86. CONCLUSIONS: Our results reflect the general good health of PTC patients. The effect on quality of life is primarily related to emotional and social impacts of treatment. The results support the measurement of a similar underlying construct, although variation in detecting changes in health exists between the instruments. Of the instruments assessed, the SF6D is the most responsive to treatment effects and should be utilized in future economic analyses in this patient population.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lubitz CC, De Gregorio L, Fingeret AL, et al. Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma. Thyroid. 2016. PMID: 27824301. doi:10.1089/thy.2016.0260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。